Clinical trials
Phase 2 Hodgkin Disease trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The Lymphoma Academic Research Organisation | 3 |
| University of Liege | 2 |
| ADC Therapeutics S.A. | 1 |
| Bristol-Myers Squibb | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Novartis Pharmaceuticals | 1 |
| Seagen Inc. | 1 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 1 |
| Universitair Ziekenhuis Brussel | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hodgkin Disease | 13 |
| Lymphoma, Non-Hodgkin | 4 |
| Lymphoma | 3 |
| Multiple Myeloma | 3 |
| Myeloproliferative Disorders | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Myelodysplastic Syndromes | 2 |
| Neoplasms | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
Trials
Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.